Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692717 | 1.00 | GPR119 (0.38) | GPR119KCNH2EIF2AK4KMT2ACHRM2 | |
| SCHEMBL7592847 | 0.90 | GPR119 (0.42) | GPR119KCNH2KMT2AKCNJ1ACACB | |
| SCHEMBL3687098 | 0.90 | GPR119 (0.42) | GPR119KCNH2KMT2AKCNJ1ACACB | |
| SCHEMBL7587789 | 0.90 | GPR119 (0.40) | GPR119KCNH2KMT2ACHRM2CHRM1 | |
| SCHEMBL3691202 | 0.90 | GPR119 (0.40) | GPR119KCNH2KMT2ACHRM2CHRM1 | |
| SCHEMBL3685203 | 0.89 | GPR119 (0.49) | GPR119KCNH2KCNJ1ACACB | |
| SCHEMBL7589821 | 0.89 | GPR119 (0.49) | GPR119KCNH2KCNJ1ACACB | |
| SCHEMBL3686890 | 0.88 | GPR119 (0.42) | GPR119KCNH2KCNJ1 | |
| SCHEMBL3689340 | 0.83 | KDM4E (0.39) | GPR119KCNH2KMT2AHRH3 | |
| SCHEMBL3695234 | 0.82 | GPR119 (0.34) | GPR119KCNH2KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8183381-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009014910-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885KCNH2 1920/4885EIF2AK4 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.